Onko Pharmaceuticals has first taken its place in pharmaceutical sector in 1987 by introducing blood derivative products in Turkey, and by getting distribution on exclusive base from the best known pharmaceutical companies of Europe. Until now Onko keeps on serving in this field by still being the leading importer of blood products through satisfying the high need of blood products in Turkey on a large scale.
In 1995, Kocsel Pharmaceuticals has joined to the family with hepatitis B vaccine and biological product group. In subsequent years, it has undertaken the mission of providing a part of Turkeys vaccine needs, which has occurred due to the attendance of Turkey to the global immunization program. After one year, as a result of success in its own sector; Onko & Kocsel Pharmaceuticals, has achieved to extend its horizon in the pharmaceutical sector by setting up an oncology business unit.
In 2002, Onko & Kocsel Pharmaceuticals took the first step on manufacturing by taking over manufacturing licenses from Roche Pharmaceuticals. This brought a new vision to Onko & Kocsel Pharmaceuticals.
Onko & Kocsel Pharmaceuticals has achieved to reflect its fast success also to its organizational structure and adapted Total Quality System to mantain professional management.
Onko & Kocsel Pharmaceuticals focused on adding new products to its mainly Oncology, Radiation Oncology, Hematology, Neurology, Infection diseases, Urology, Physical Medicine & Rehabilitation, Orthopedics, Rheumatology, Immunology, Dermatology and Internal Medicine portfolio year after year. With its dedicated staff and well organized and positioned structure Onko & Kocsel Pharmaceuticals has reached its target consumers throughout Turkey. In the medical marketing; strong professional customer-focused relations, effective meeting organizations, effective communication skills, power of investment and clinically-focused scientific approaches have constituted its vision. Onko & Kocsel Pharmaceuticals plays a significant role with well-educated, professionally trained, experienced, dynamic and result oriented sale force.
Onko & Kocsel keeps showing promising rise by signing new business agreements with strong companies and expanding its product portfolio in the light of innovative and stable development. Onko & Kocsel Pharmaceuticals looks ahead with confidence with an experience more than 20 years in the Pharmaceutical market.
Contact Details Onko ilaç San. ve Tic. A.Ş.
Koşuyolu Cad. No:34 34718 Koşuyolu Kadıköy – İstanbul / Türkiye
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
After a significant experience in consumer goods at Procter & Gamble, you have been managing director of Janssen Turkey for 11 years. Over this last decade, the Turkish pharma market…
Poland and Turkey present many similarities, in terms of market size and frequency of reforms for instance, but also a lot of differences, as the generic penetration is much lower…
Currently, what are the main priorities and goals of ISPAT related to the Healthcare and Pharmaceuticals sector, and what are the overall strategies designed to achieve these objectives? As an…
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Can you describe the current investment climate in Turkey for pharma companies? Turkey’s economic and political situation are very important factors to consider for foreign investors. Over the last three…
Mr. Ediz Günsel, could you introduce yourself to our readers ? Yes; I have been with the firm over twenty years, including 5 years with PwC London. In my twenty…
At Reckitt Benckiser, you have gradually taken positions of increasing responsibility over the last decade in Marketing. What would you highlight as the main specificities of Turkish market compared to…
The company entered the Turkish market in 2005, and made important product launches in 2008. You have been General Manager of Ferring Turkey over those last 7 years. Can you…
Would you like to come back for our readers on the main milestones in Daiichi Sankyo’s development over the past few years in Turkey and how it positions itself in…
You have pharmaceuticals production in your background and have recently joined PharmaVision as General Manager. To what extent does this speak about the company’s direction? Could you elaborate on your…
Mr Fadıllıoğlu, after a previous position at Abbott, you were recently appointed head of GSK Turkey. How different is GSK as an organization? What new therapeutic areas, processes, or corporate…
Mr Acar, could you present to our readers the Institution’s historical development and its role today in the Turkish pharmaceutical and healthcare sector? Before Social Security Reform was initiated, there…